MedTrace Logo

AnaConDa-therapy in COVID-19 Patients

NCT05586126 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2022-10-19

No results posted yet for this study

Summary

COVID 19-pneumonia may evolve into respiratory insufficiency for which invasive mechanical ventilation is required. Recently, inhaled anesthetics have become available for sedation of critically ill patients. Based upon recent research, these anesthetics may provide advantages in improvement of P/F ratio in ARDS patients. However, up to now, its effects on COVID-19 pneumonia patients is unknown; therefore, this study was designed as a plan to investigate whether the use of inhaled sevoflurane leads to improvement of oxygenation compared to intravenous sedatives in mechanically ventilated COVID-19 patients

Conditions

Interventions

DRUG

Sevoflurane

sevoflurane inhalation

Sponsors & Collaborators

  • Jeroen Bosch Ziekenhuis

    lead OTHER

Principal Investigators

  • D. van Nieuwenhuizen, RN · Jeroen Bosch Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-01-27
Completion
2022-07-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05586126 on ClinicalTrials.gov